On July 28th, EMD Serono showcased the growth of our Global Research and Development headquarters located in Billerica, MA. The Clinical Operations Team hosted our recruiting vendors. The team highlighted: - the patient centric approach of our trials - desired innovative talent profiles - projected growth - continued investment in biopharmaceutical R&D

2. Company presentation2
Founded in Darm-
stadt, Germany, in
1668 by Friedrich
Jacob Merck, we are
the world’s oldest
pharmaceutical and
chemical company.
Today, the Merck
family remains the
majority owner of
the company.
Over the course
of nearly 350
years, we have
become a truly
global company.
Our approximately
50,000 people work
in 66 countries and
are united by their
passion for new
ideas, the
possibilities of tech-
nology, and the
potential to make
a difference in the
world.
Our company
name is Merck
KGaA, Darmstadt,
Germany.
In the United States
and Canada we
operate as EMD
Serono in the
Biopharma business,
as MilliporeSigma in
the Life Science
business, and as
EMD Performance
Materials in the
materials business.
We live in a world of
possibilities.
A world where exploration and
discovery are celebrated. Our
meticulous and research-driven
businesses deliver diverse, high-
quality products that enrich lives
and enable us to share business
success with our customers.
Our
company

3. 1668
founded
Company presentation3
HEALTHCARE,
LIFE SCIENCE
& PERFORMANCE
MATERIALS
66
countries
50,000
employees
€1.7 bn
invested in R&D
in 2015
€12.8 bn
sales in 2015

4. History and future
Nearly 350 years of experience for patients and customers
Company presentation4
Friedrich Jacob
Merck purchases
the Angel
Pharmacy (Engel-
Apotheke) in
Darmstadt
Emanuel Merck
begins production
on an industrial
scale
Merck from
Darmstadt,
Germany is
represented on
all continents
Our U.S. subsidi-
ary Merck & Co.
is expropriated
as a consequence
of World War I
All foreign
subsidiaries
are lost and the
company starts
up again from
the ruins in
Darmstadt
Our subsidiaries
are founded or
reestablished
around the world
We enter the field
of biotechnology,
assuming a pio-
neering role
in Germany
The Institute
for Experimental
Drug Research
is established
Initial public
offering
Acquisition
of Serono
Acquisition
of Millipore
We take up
the fight against
schistosomiasis,
aiming to elim-
inate this tropical
disease in Africa
Acquisition of
AZ
Electronic
Materials
Our 350th
anniversary
Acquisition of
Sigma-Aldrich

5. Company presentation5
What we do
Life Science
Performance
Materials
Healthcare
A wide range of specialty chemicals,
such as liquid crystals for displays,
effect pigments for coatings and
cosmetics, or high-tech materials
for the electronics industry.
Innovative tools and laboratory
supplies for the life science industry
that make research and biotech
production easier, faster and more
successful.
Prescription medicines to treat, for
example, cancer, multiple sclerosis
and infertility, over-the-counter
pharmaceuticals for everyday health
protection or to provide fast relief of
colds and pain, as well as innovations
in the areas of allergies and
biosimilars.

6. Merck R&D employees work
As One for Patients and are
dedicated to turning great
science into treatment options to
meet unmet medical needs.

7. Company presentation7
Healthcare
Our development pipeline
April 21st, 2016
M2736 (ATX-MS-1467)
Immune tolerizing agent
Multiple sclerosis
Tepotinib
c-Met kinase inhibitor
Non-small cell lung cancer
Tepotinib
c-Met kinase inhibitor
Hepatocellular cancer
Avelumab1
Anti-PD-L1 mAb
Merkel cell carcinoma
Sprifermin
Fibroblast growth factor 18
Osteoarthritis
Atacicept
Anti-Blys/anti-APRIL fusion protein
Systemic lupus erythematosus
Tepotinib
c-Met kinase inhibitor
Solid tumors
M2698
p70S6K & Akt inhibitor
Solid tumors
M3814
DNA-PK inhibitor
Solid tumors
Beigene-283
BRAF inhibitor
Solid tumors
Avelumab1
Anti-PD-L1 mAb
Solid tumors
M9241 (NHS-IL12)2
Cancer immunotherapy
Solid tumors
M7824
Bifunctional immunotherapy
Solid tumors
M1095 (ALX-0761)
Anti-IL-17 A/F nanobody
Psoriasis
M2951
BTK inhibitor
Systemic lupus erythematosus
Pending
Submission/Review
Phase IIIPhase IIPhase I
Cladribine Tablets –
Lymphocyte targeting agent
Relapsing-remitting multiple sclerosis
Pipeline products are under clinical investigation and have not been proven to be safe and effective.
There is no guarantee any product will be approved in the sought-after indication.
Neurodegenerative Diseases
Oncology
Immunology
Immuno-Oncology
Avelumab1 - Anti-PD-L1 mAb
Non-small cell lung cancer 1L3
Avelumab1 - Anti-PD-L1 mAb
Non-small cell lung cancer 2L4
Avelumab1 - Anti-PD-L1 mAb
Gastric cancer 1L3
Avelumab1 - Anti-PD-L1 mAb
Gastric cancer 3L5
Avelumab1 - Anti-PD-L1 mAb
Bladder cancer 1L3
Avelumab1 - Anti-PD-L1 mAb
Ovarian cancer platinum resistant/refractory
Avelumab1 - Anti-PD-L1 mAb
Renal cell carcinoma 1L3
MSB11022
Proposed biosimilar of Adalimumab
Chronic Plaque Psoriasis
1Avelumab is the proposed International Non-proprietary Name (INN) for the anti-PD-L1 monoclonal antibody (previously known as MSB 0010718C)
2Sponsored by the National Cancer Institute (USA)
3 First Line treatment
4Second Line treatment
5Third Line treatment
Biosimilars

8. To implement the industry’s most
comprehensive compendium of activities that
truly reflect the needs of the patients who
volunteer to participate in EMD Serono
clinical trials by incorporating the “voice of
the patient” into both the design and
operational implementation.
Patient Centricity Vision
Patient
Centric
Trials
Patient
Engagement
Mechanism
to collect
patient input
Enabling
Technology
and Tools
Clinical
Trial
End Points
(What, How)
Patient
Dialog
and
Feedback
Patient
Input

9. N.N.
Juergen Reindl
Chief of Staff & GCO
Communications
HR Business Partner
Diane Siegel
Regional
Clinical
Operations
Maria
Koutsopoulou
GCO
External
Innovation
Paulo
Moreira
Clinical Quality
Management
N.N.
Global Clinical
Systems &
Data Sciences
Graham
Downing
Financial
Planning &
Analysis
David
Schumacher
Clinical
Operations
Asian Hubs
Kathleen Ford
Head of GCO
Service
Provider
Management
Christopher
Rull
Clinical Trial
Management
Jacqueline
Curtiss
Bianka Kolb
Executive Assistant
9 GCO Org Chart
Global Clinical Operations August 2016

10. Merck KGaA
Darmstadt, Germany
Dave Anderson, SRDI, 28 JULY 2016
Overview of the Billerica Expansion
RECRUITING OPEN
HOUSE

11. 11
• Employees will choose where and how to work at any given time.
• Seating for 120-130: 4 ‘neighborhood’ style areas
• Focus on team performance and collaboration
• 200+ additional seats in a variety of settings
• Quiet zones, telephone, huddle, conference rooms, indoor and
outdoor café areas, outside patios, casual bleacher-style area…
• A 100-person auditorium to create an academic feel
• Pursuing LEED (Leadership in Energy and Environmental Design)
certification, creating a building that is good for the environment
• Pursuing WELL Building certification, creating a building that is
good for our people
 We are in the first 100 registered WELL projects globally
 One of 2 projects in MA, and the first in new construction
Billerica Expansion of the Serono Research & Development Institute
The Power of Choice

12. 12
Design Themes

13. 13
Design Themes

14. 14
Design Themes

18. 18
Welcome to the new Sagamore Building! Opening June 2017

19. How do I become a preferred vendor with EMD Serono?
1) Reach out to Dave Anderson, Key Account Lead for North America Healthcare OR one of the Recruiting
Leads
Luke Hubbard - Research & Development
Amy Carr – US Commercial & Global Franchise business
***If already a preferred vendor, our team will contact you based on your team’s niche space for support.
2) Recruiter will arrange for a contract to be initiated and request you be added to our ATS.
3) Global team will send login credentials (1 individual per company) and Recruiter will add you to the
requisition to be worked on. A portal guide will also be provided at initial set up.
19 Vendor Meeting| 07.28.2016

20. 20 Vendor Meeting| 07.28.2016
Job Listings
A list of all Requisitions that have been posted to your Agency. From here you can submit new candidates or existing candidates to any of
these Requisitions
Upon logging in Agencies are able to see and do the following:
Candidate List
A list of all candidates that were submitted by your Agency and their status on what positions they were submitted to
Note: this list includes ALL candidates submitted by Recruiters from your Agency, not just ones you personally submitted

21. Submitting a candidate
To submit a new or existing candidate use the Take Action drop down from the Job Listing tab
21 Vendor Meeting| 07.28.2016
You will then be required to submit basic information about your candidate and attach their resume (Note:
you must agree that this candidate has given permission for you to submit his/her profile)
Please note: The uploaded file will be visible to the candidate if he/she logs
into his/her profile. Please make sure to not upload any confidential
information.
The Recruiter will review the submitted candidates in the system and if
interested, they will invite the candidate to apply. The candidate will receive an
email directing them to the job and the application.

22. Questions – Please contact Shelby Briggs
Shelby.Briggs@emdserono.com
Telephone: +1 (781) 681 - 2471
22